Skip to main content
U.S. Department of Health and Human Services
—
National Institutes of Health
Create Account
Login
Main menu
Discover
Share
Create
Learn
Mitogen-activated protein kinase kinase 1 (MEK1) in complex with CH4858061 and MgATP
Autogenerated by
for
Nuclear Juicer
Created on Mon, 2022-06-27 12:35, last updated on Mon, 2022-06-27 13:02
I Printed This
Remix It
Vertical Tabs
General Information
This Model was autogenerated from the
"Quick Submit"
tool.
Model ID
3DPX-017281
Category
Proteins, Macromolecules and Viruses
Keyword(s)
KINASE, kinase inhibitor, allosteric, TRANSFERASE-TRANSFERASE INHIBITOR complex
Protein Data Bank ID
3OS3
Experimental Method
X-RAY DIFFRACTION
Resolution
2.77
Model Details
Associated Species
Escherichia coli
Oligomeric Details
monomeric
Scattering Type
x-ray
Attribution
PubMed ID
21 316 218
Digital Object Identifier (DOI)
10.1016/j.bmcl.2011.01.062
Citation Title
Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent.
Journal
Bioorg.Med.Chem.Lett.
Citation Year
2011
STL/VRML Files
PDB-3OS3-ribbon-secondary.wrl
PDB-3OS3-ribbon-rainbow.wrl
PDB-3OS3-ribbon-bychain.wrl
PDB-3OS3-ribbon.stl
PDB-3OS3-surf-bychain.wrl
PDB-3OS3-surf-hydropathy.wrl
PDB-3OS3-surf-coulombic.wrl
PDB-3OS3-surf.stl
PDB-3OS3.zip
X3D Files
PDB-3OS3-ribbon-secondary.x3d
PDB-3OS3-ribbon-rainbow.x3d
PDB-3OS3-ribbon-bychain.x3d
PDB-3OS3-ribbon.x3d
PDB-3OS3-surf-bychain.x3d
PDB-3OS3-surf-hydropathy.x3d
PDB-3OS3-surf-coulombic.x3d
PDB-3OS3-surf.x3d
Rating
Select rating
Give Mitogen-activated protein kinase kinase 1 (MEK1) in complex with CH4858061 and MgATP 1/5
Give Mitogen-activated protein kinase kinase 1 (MEK1) in complex with CH4858061 and MgATP 2/5
Give Mitogen-activated protein kinase kinase 1 (MEK1) in complex with CH4858061 and MgATP 3/5
Give Mitogen-activated protein kinase kinase 1 (MEK1) in complex with CH4858061 and MgATP 4/5
Give Mitogen-activated protein kinase kinase 1 (MEK1) in complex with CH4858061 and MgATP 5/5
Cancel rating
No votes yet
Licensing
Comments
0